Targeted Deep Sequencing in Untreated Progressive CLL Helps to Better Dissect the Genomic Landscape and Shows Novel Associations between Mutations, Prognostic and Clinical Parameters: Data from E1912, a Randomized Phase III Study of the ECOG-ACRIN Cancer Research Group

Esteban Braggio,Victoria Wang,Laura Ann Bruins,Santiago Barrio,Connie Lesnick,Jacqueline C Barrientos,Susan M O'Brien,Martin S Tallman,Mark R Litzow,Rafael Fonseca,Neil E Kay,Tait D Shanafelt

doi:10.1182/blood.v130.suppl_1.4288.4288

Targeted Deep Sequencing in Untreated Progressive CLL Helps to Better Dissect the Genomic Landscape and Shows Novel Associations between Mutations, Prognostic and Clinical Parameters: Data from E1912, a Randomized Phase III Study of the ECOG-ACRIN Cancer Research Group

Esteban Braggio, Victoria Wang + Show 10 more

https://doi.org/10.1182/blood.v130.suppl_1.4288.4288

Copy DOI

Journal: Blood

Publication Date: Jun 25, 2021

Affiliation: Mayo Clinic, IIT@Harvard, University Hospital Würzburg, Hofstra University, University of California, Irvine Medical Center, Memorial Sloan Kettering Cancer Center

#Mutations In NOTCH1 #Untreated Chronic Lymphocytic Leukemia + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

Targeted Deep Sequencing in Untreated Progressive CLL Helps to Better Dissect the Genomic Landscape and Shows Novel Associations between Mutations, Prognostic and Clinical Parameters: Data from E1912, a Randomized Phase III Study of the ECOG-ACRIN Cancer Research Group

Full Text